Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention provides compounds of Formula (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention provides compounds of Formula (I): (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: Disclosed herein is a series of helical sulfono-?-AApeptides that mimic the binding mode of the ?-helical HD2 domain of B-Cell Lymphoma 9 (BCL9). As disclosed herein, sulfono-?-AApeptides can structurally and functionally mimic the ?-helical domain of BCL9, and selectively disrupt ?-catenin/BCL9 PPIs with even higher potency. More intriguingly, these sulfono-?-AApeptides can enter cancer cells, bind with ?-catenin and disrupt ?-catenin/BCL PPI, and exhibit excellent cellular activity, which is much more potent than the BCL9 peptide. Furthermore, enzymatic stability studies demonstrated the remarkable stability of the helical sulfono-?-AApeptides, with no degradation in the presence of pronase for 24 h, augmenting their biological potential.

Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X1, X2, X3, and X4 are each independently CR6 or N; provided that no more than two of X1, X2, X3, or X4 are N; Q2 is N or NR5a; one of Q1 and Q3 is CR5, and the other is N or NR5a; and the dashed circle denotes optional bonds forming an aromatic ring; Y1 is O or NR3; Y2 is —CO—, —SO2—, or —S(O(NH)—; Y3 is O or NR4a; provided that (1) Y1 and Y3 are not both O, and (2) when Y2 is C(O), Y1 is not O; L is a covalent bond or C1-4 alkylene substituted with 0 to 4 R7; R1 is (—CH2)aR9; a is an integer of 0 or 1; R2 is each independently halo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl, C4-6 heterocyclyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxy, alkoxyalkyl, haloalkoxyalkyl, or haloalkoxy; n is an integer of 0, 1, or 2; R3 and R4a are independently hydrogen, C1-6 alkyl, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or

Abstract: The invention relates to an automated driving control system, including: a data exchange unit configured to obtain video data streams and distribute the video data streams to at least one computing unit; the at least one computing unit configured to compute perception result data based on the video data streams; a sensor fusion unit configured to fuse the perception result data and sensor data, to obtain fusion result data; and a planning control unit configured to generate a driving control instruction based on the fusion result data, where the planning control unit or the sensor fusion unit is configured to provide a bypass of the data exchange unit. When anomalies occur in any of the units, the automated driving control system may provide a corresponding bypass to keep an automated driving function going.

Abstract: Introduced here are risk management platforms able to implement an automated framework designed to manage, parse, and analyze data for purposes of facilitating compliance with relevant policies in a distributed computer environment. By implementing the technology described herein, an entity can ensure that it complies with the latest regulatory policies, recognizes emerging risks, and conducts more efficient operational planning. A risk management platform can generate interfaces through which an individual (also referred to as a “user”) can interact with the risk management platform. Through these interfaces, the user can apply programmed models to financial data associated with an entity to predict the performance of the entity under various economic scenarios.

Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: A method for preparing artificial graphite includes (A) preparing heavy oil, and forming coke from the heavy oil through continuous coking reaction such that the coke has a plurality of mesophase domains, wherein a size of the mesophase domains ranges between 1 and 30 ?m by polarizing microscope analysis; and (B) processing the coke formed by step (A) sequentially by pre-burning carbonization treatment, grinding classification, high-temperature carbonization treatment and graphitization treatment to form polycrystalline artificial graphite from the coke. The method for preparing artificial graphite of the present invention and the polycrystalline artificial graphite prepared thereby are applicable to batteries.

Abstract: The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention provides compounds of Formula (Ia) or (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: A method for enhancing network coverage based on adaptive generation of resource cell. A traditional cell in a network is taken as an initial state of the network. A correlation matrix in a current network state is generated. Whether |?i,jt??i,jt-1|/?i,jt-1>? is determined. Each access point is divided into a plurality of resource cells. A CU-DU network mapping table is generated. A middlehaul link of each of the plurality of resource cells is constructed according to the CU-DU network mapping table.

Abstract: The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention provides compounds of Formula (Ia) or (Ib):Formula (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: A wafer-level assembly method for a micro hemispherical resonator gyroscope includes: after independently manufactured glass substrates are softened and deformed at a high temperature, forming a micro hemispherical resonator on the glass substrate; forming glass substrate alignment holes at both ends of the glass substrate by laser ablation; aligning and fixing a plurality of identical micro hemispherical resonators on a wafer fixture by using the alignment holes as a reference, and then performing operations by using the wafer fixture as a unit to implement subsequent processes that include: releasing the micro hemispherical resonators, metallizing the surface, fixing to the planar electrode substrates, separating the wafer fixture and cleaning to obtain a micro hemispherical resonator gyroscope driven by a bottom planar electrode substrate.

Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: A rigid corneal contact lens comprises a front-surface optical zone and a back-surface optical zone: the front-surface optical zone comprises a front-surface central zone (1) and a defocusing zone (2) at the periphery of the front-surface central zone (1); the front-surface central zone (1) is spherical; the defocusing zone (2) has a radius of curvature decreasing from the outside of the front-surface central zone (1) continuously and a minimum radius of curvature which ranges from 95% to 50% of the radius of curvature of the front-surface central zone (1). Because of the structure of a human eye, the phenomenon of peripheral hyperopic defocus exist in human eyes, that is, central image points for an image are projected on macula foveal of retina and peripheral image points are projected behind retina. As shown in experimental evidences, peripheral hyperopic defocus is the main cause of myopia development which can be moderated by restraining peripheral hyperopic defocus.